James L. L.  Tullis net worth and biography

James Tullis Biography and Net Worth

Director of Alphatec
James L.L. Tullis has served as a Director since March 2018. With a career of over 40 years in healthcare investing, he currently serves as the Chairman at Tullis Health Investors, a position he has held since 1985. Prior to founding Tullis Health Investors, Mr. Tullis was senior vice president of E.F. Hutton &Co. and a principal at Morgan Stanley & Co. where he led healthcare investment research and, later, healthcare investment banking. During his tenure at Morgan Stanley, he received recognition 14 times on the Institutional Investor All-Star list of Wall Street’s top securities analysts and was twice named #1 Drug Analyst and was featured on the Wall Street Week television program. He also serves as a Director of Lord Abbett family of mutual funds; Crane Corporation; electroCore, LLC; Exagen Diagnostics, Inc.; LivHOME, Inc.; and SupplyPro, Inc.. Mr. Tullis earned an M.B.A. from Harvard Business School and BA from Stanford University.

What is James L. L. Tullis' net worth?

The estimated net worth of James L. L. Tullis is at least $15.43 million as of June 15th, 2023. Mr. Tullis owns 1,515,839 shares of Alphatec stock worth more than $15,431,241 as of April 14th. This net worth evaluation does not reflect any other assets that Mr. Tullis may own. Learn More about James L. L. Tullis' net worth.

How do I contact James L. L. Tullis?

The corporate mailing address for Mr. Tullis and other Alphatec executives is 5818 EL CAMINO REAL, CARLSBAD CA, 92008. Alphatec can also be reached via phone at (760) 431-9286 and via email at ir@alphatecspine.com. Learn More on James L. L. Tullis' contact information.

Has James L. L. Tullis been buying or selling shares of Alphatec?

James L. L. Tullis has not been actively trading shares of Alphatec during the last ninety days. Most recently, James L. L Tullis sold 30,000 shares of the business's stock in a transaction on Wednesday, March 8th. The shares were sold at an average price of $16.12, for a transaction totalling $483,600.00. Following the completion of the sale, the director now directly owns 467,974 shares of the company's stock, valued at $7,543,740.88. Learn More on James L. L. Tullis' trading history.

Who are Alphatec's active insiders?

Alphatec's insider roster includes Evan Bakst (Director), Jeffrey Black (CFO), David Demski (Director), Jason Hochberg (Director), Craig Hunsaker (EVP), John Koning (Chief Financial Officer), Scott Lish (SVP), Tyson Marshall (General Counsel & Corporate Secretary), Patrick Miles (CEO), David Mowry (Director), David Pelizzon (Director), Jennifer Pritzker (Major Shareholder), Paul Segal (Major Shareholder), David Sponsel (EVP), and James Tullis (Director). Learn More on Alphatec's active insiders.

Are insiders buying or selling shares of Alphatec?

In the last twelve months, Alphatec insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $283,500.00. In the last twelve months, insiders at the medical technology company sold shares 14 times. They sold a total of 425,053 shares worth more than $4,855,334.27. The most recent insider tranaction occured on March, 7th when CEO Patrick Miles sold 12,691 shares worth more than $135,032.24. Insiders at Alphatec own 22.8% of the company. Learn More about insider trades at Alphatec.

Information on this page was last updated on 3/7/2025.

James L. L. Tullis Insider Trading History at Alphatec

See Full Table

James L. L. Tullis Buying and Selling Activity at Alphatec

This chart shows James L L Tullis's buying and selling at Alphatec by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$400k-$200k$0$200k$400kTotal Insider BuyingTotal Insider Selling

Alphatec Company Overview

Alphatec logo
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Read More

Today's Range

Now: $10.18
Low: $9.88
High: $10.19

50 Day Range

MA: $10.47
Low: $9.27
High: $12.53

2 Week Range

Now: $10.18
Low: $4.88
High: $13.79

Volume

679,190 shs

Average Volume

2,130,389 shs

Market Capitalization

$1.47 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2